AstraZeneca earnings report

Note: This section contains information in English only.
Source: Dukascopy Bank SA
AstraZeneca showed strong results for the first nine months of 2025, with total revenue up 11% to $43.2 billion and core earnings per share up 15% to $7.04. Growth came from all main therapy areas and regions, led by strong sales in cancer, respiratory, and heart and kidney medicines. The company achieved 16 positive Phase III trial results this year, including major successes for Enhertu, Imfinzi, and baxdrostat.



AstraZeneca also broke ground on a $4.5 billion manufacturing site in Virginia, signed a deal with the U.S. government to make medicines more affordable, bought SixPeaks Bio, and updated its Koselugo partnership with Merck. It kept its 2025 guidance for high single-digit revenue growth and low double-digit earnings growth, and Moody's upgraded its credit rating to A1.
Back to articles

Actual Topics

Subscribe to "Fundamental Analysis" feed

Subscribe
Per scoprire di più sulla piattaforma di Dukascopy Bank per Forex/CFD, sul SWFX ed altre informazioni relative al trading,
la preghiamo di contattarci o richiedere di essere contattato (callback request)
For further information regarding potential cooperation,
please call us or make callback request.
To learn more about Dukascopy Bank Binary Options / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
Per scoprire di più sulla piattaforma di Dukascopy Bank per Forex/CFD, sul SWFX ed altre informazioni relative al trading,
la preghiamo di contattarci o richiedere di essere contattato (callback request).
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.